Short answer
REGENXBIO Inc. (RGNX) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results for quarter ended June 30, 2026.
REGENXBIO Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026
- Press release issued August 6, 2026
- Detailed financial results and operating commentary in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $108.0M vs $21.4M, driven by $100.0M AbbVie milestone; net income $22.7M vs $70.9M loss
- RGX-202 AFFINITY DUCHENNE met its primary endpoint with p<0.0001, supporting Q3 2026 BLA initiation and potential 2H 2027 approval
- Wet AMD pivotal ATMOSPHERE and ASCENT topline data expected Q4 2026, creating a major near-term valuation catalyst
- July capital exceeded $200M, including $100M milestone and $107.8M offering proceeds; pro forma liquidity approximately $313M
- Cash runway extended into Q4 2027, while dilution increased common shares outstanding to 54.164M from 50.892M since December 2025
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other REGENXBIO Inc. 8-K filings
Get the next RGNX 8-K as it lands
Follow RGNX for push alerts, or ask the research agent what this filing means.